tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
IMCR
Immunocore Holdings
Stock Analysis
Analyst Forecasts
Technical Analysis
Options
Chart
Earnings
Dividends
Ownership
Financials
News & Insights
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding IMCR?
Track your performance easily
Link Broker

Immunocore Holdings (IMCR) Stock News & Sentiment

152 Followers
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Premium
Press Releases
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
6d ago
IMCR
Immunocore to present at the 2024 Cantor Global Healthcare Conference
Premium
Press Releases
Immunocore to present at the 2024 Cantor Global Healthcare Conference
7d ago
IMCR
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Premium
Press Releases
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
2M ago
IMCR
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Premium
Press Releases
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
4M ago
IMCR
Immunocore Reveals Promising Brenetafusp Trial Results
Premium
Company Announcements
Immunocore Reveals Promising Brenetafusp Trial Results
4M ago
8K
IMCR
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Premium
Press Releases
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
4M ago
IMCR
Immunocore to present at the Jefferies Global Healthcare Conference
Premium
Press Releases
Immunocore to present at the Jefferies Global Healthcare Conference
4M ago
IMCR
More IMCR News >

IMCR News on the Web

Buy Rating Affirmed for Immunocore Holdings Amid Promising Clinical Results and Strategic Expansion
TipRanks News
Bullish
Buy Rating Affirmed for Immunocore Holdings on Strong Clinical Trial Results and Solid Financial Analysis
TipRanks News
Bullish
Immunocore Holdings plc : Short Seller Sentiment is Bearish on This Cancer Stock
Yahoo Finance
Neutral
Immunocore to present at the 2024 Cantor Global Healthcare Conference
Yahoo Finance
Neutral
Significant Portfolio Addition: T. Rowe Price Investment Management, Inc. ...
GuruFocus News
Bullish
Immunocore Holdings (IMCR) Receives a Buy from Barclays
TipRanks News
Bullish
Immunocore Holdings plc : Top ADR Stock According to Hedge Funds
Yahoo Finance
Neutral
Buy Rating Affirmed for Immunocore Holdings on Strong Kimmtrak Performance and Market Dominance
TipRanks News
Bullish

News Score - Last 7 Days

Positive
IMCR
Sector Average
Media Buzz
This Week3 articles
Weekly Average1.75 articles
News Sentiment
This Week100%
Sector Average61%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IMCR’s Media Buzz Sentiment?
3 articles about IMCR were published this week. In an average week, 1.75 articles are published.
    What is IMCR’s weekly average amount of articles?
    In an average week, 1.75 articles about IMCR are published.
      What is IMCR’s News Sentiment?
      100% of articles about IMCR were positive this week, compared to its sector average of 61%.
        Healthcare Stocks that are Trending in the News
        NUVLNuvalent
        EPIXESSA Pharma
        INCYIncyte
        EWTXEdgewise Therapeutics
        BLCOBausch + Lomb Corporation
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing